on Immunic AG
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
NEW YORK, August 28, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company focused on therapies for chronic inflammatory and autoimmune diseases, will host a Multiple Sclerosis Research and Development (R&D) Day and attend several conferences in September.
On September 10, Immunic’s MS R&D Day will feature discussions on MS treatment and their lead asset, vidofludimus calcium (IMU-838). The session will include presentations from industry experts Francesca Montarolo and Amit Bar-Or.
From September 18-20, Immunic will participate in the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen. The company will present data on vidofludimus calcium and its effects on MS.
Other events include the DMDG 50th Open Meeting from September 2-4 in York, UK, and the 20th International Celiac Disease Symposium in Sheffield, UK, from September 5-7. Additionally, Immunic will be at the 2024 Cantor Fitzgerald Global Healthcare Conference from September 17-19 in New York.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Immunic AG news